Asia Pacific Intradermal Injections Market

The intradermal injections market in Asia Pacific is expected to grow from US$ 774.05 million in 2021 to US$ 1,698.43 million by 2028. It is estimated to grow at a CAGR of 11.9% from 2021 to 2028. 

Developed and Developing Countries Provide Significant Growth Opportunities to Market

Health systems in developing economies focus on introducing various advanced therapeutic, diagnostic, and aesthetic technologies into their service portfolios to be able to provide healthcare facilities with high efficiency. In developed countries, intradermal devices have received significant acceptance in vaccination and cosmetic procedures. In developing countries, although these devices are mainly used in vaccination, tuberculosis diagnosis, and aesthetic procedures, the market is currently in a nascent stage of development. Many developing countries are attractive destinations for medical tourism, especially for aesthetic procedures due to the lower costs of these procedures than developed countries. Health facilities, medical spas, and wellness centers in developing countries are increasingly offering a comprehensive range of inexpensive but high-quality medical-aesthetic procedures, which, eventually, triggers the demand for intradermal injections. The leading manufacturers of intradermal injections are developing ideal devices and collaborating with other players to improve the therapeutic efficacy of existing and new drugs. Asia Pacific is expected to be the fastest-growing market for intradermal injections among all major regions, with countries such as China, Japan, India, and South Korea being prime contributors to the market growth, during the forecast period. The rapid pace of urbanization, surging investments by healthcare providers in improving infrastructure, growing awareness among the population, and increasing availability of a range of advanced products and technologies are all contributing to the growth of this market.

Market Overview

The Asia Pacific intradermal injections market is segmented into Australia, China, India, Japan, South Korea, and Rest of Asia Pacific. The market growth in the region is ascribed to the growing investments from international players in China and India with greater government support, expanding base of CRO service providers, and advancements in healthcare infrastructure. The medical device industry in China has grown at a faster pace in the past several years. This growth can be attributed to China’s 13th Five-Year Plan that prioritizes health and innovation, increased demand for technologically advanced medical devices, significantly rising geriatric population, and growing chronic health conditions among people. In addition, the availability of low-cost and skilled laborers and massive space for production facilities have encouraged various market leaders to have their production plants in China. The Population Reference Bureau has projected that 366 million people in China will be aged 65 or more by 2050. Per the WHO’s Ageing and Health in China, in 2019, ~75% of people with age 60 and above suffered from noncommunicable diseases, such as cardiovascular disease, diabetes, and hypertension. The R&D sector of China is focused on develop devices for painless delivery of drugs via intradermal route, which can specifically of help during the procedures involving elderly populations.

Asia Pacific Intradermal Injections Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Intradermal Injections Strategic Insights

Strategic insights for the Asia Pacific Intradermal Injections provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Intradermal Injections Report Scope

Asia Pacific Intradermal Injections Regional Insights

The geographic scope of the Asia Pacific Intradermal Injections refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Intradermal Injections Market Segmentation 

The Asia Pacific intradermal injections market is segmented on the basis of method, application, end user, and country. 

Based on method, the market is segmented into normal sized needle, short needle, and without needle. The normal sized needles segment registered the largest market share in 2021. The normal sized needles segment is further subsegmented into intradermal microinjections, microneedle arrays, and tattoo devices. The short needle segment is bifurcated into intradermal liquid jet injectors and ballistic intradermal injectors. 

In terms of application, the Asia Pacific intradermal injections market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held the largest market share in 2021. 

The Asia Pacific intradermal injections market, by end user, is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held the largest market share in 2021. 

Based on country, the market is segmented into Australia, China, India, Japan, South Korea, and rest of Asia Pacific. China dominated the market share in 2021. 

BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; EUNSUNG GLOBAL; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd are the leading companies operating in intradermal injections market in the Asia Pacific region.